Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...
Number 5: The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the ...
Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...
Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback